| The efficacy of glatiramer acetate in beta-interferon-intolerant MS patients. | |
| | |
MedLine Citation:
|
PMID: 16146492 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
OBJECTIVES: Glatiramer acetate (GA) is routinely used in multiple sclerosis (MS) patients who cannot tolerate or fail to respond to beta-interferon (IFN-beta). The aim of this study was to assess the efficacy and tolerability of GA in these patients. METHODS: Fifteen relapsing-remitting MS patients who had discontinued IFN-beta therapy due to side effects were included in this open, 1-year prospective study. Neurologic examinations and laboratory assessments were performed every 3 months. The induction of MxA protein production was also evaluated. RESULTS: Eleven of fifteen patients (73%) tolerated GA well whereas four patients (27%) discontinued treatment due to side effects. The relapse rate reduced from 1.86 per year to 0.91 per year. Neither laboratory abnormalities nor MxA protein induction was found. CONCLUSION: GA can be considered as a good treatment alternative to IFN-beta-intolerant MS patients. However, some patients were not able to use available immunomodulative treatments, which emphasizes the need for new therapeutic options. The lack of MxA protein induction confirms the different mechanisms of action of GA and IFN-beta. |
| | |
Authors:
|
A M Vallittu; J Peltoniemi; I Elovaara; H Kuusisto; M Färkkilä; J Multanen; J P Erälinna |
Publication Detail:
|
Type: Clinical Trial; Journal Article |
Journal Detail:
|
Title: Acta neurologica Scandinavica Volume: 112 ISSN: 0001-6314 ISO Abbreviation: Acta Neurol. Scand. Publication Date: 2005 Oct |
Date Detail:
|
Created Date: 2005-09-08 Completed Date: 2005-10-25 Revised Date: 2006-08-16 |
Medline Journal Info:
|
Nlm Unique ID: 0370336 Medline TA: Acta Neurol Scand Country: Denmark |
Other Details:
|
Languages: eng Pagination: 234-7 Citation Subset: IM |
Affiliation:
|
Department of Virology, University of Turku, Turku, Finland. anna-maija.vallittu@utu.fi |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Adjuvants, Immunologic
/
adverse effects Adult Female Humans Immunosuppressive Agents / administration & dosage*, adverse effects Interferon-beta / adverse effects Male Middle Aged Multiple Sclerosis, Relapsing-Remitting / drug therapy* Peptides / administration & dosage*, adverse effects Prospective Studies Treatment Outcome |
| Chemical | |
Reg. No./Substance:
|
0/Adjuvants, Immunologic; 0/Immunosuppressive Agents; 0/Peptides; 0/copolymer 1; 77238-31-4/Interferon-beta |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Cognitive performance in cryptogenic epilepsy.
Next Document: Analysis of Chlamydia pneumoniae-specific oligoclonal bands in multiple sclerosis and other neurolog...